Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.
about
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agentSubtractive immunization yields monoclonal antibodies that specifically inhibit metastasis92-kD type IV collagenase mediates invasion of human cytotrophoblasts.The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression.Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3'-untranslated region.Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells.TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes.Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradationHepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.P52PAI-1 gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphological response.Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancyRegulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta.Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1.HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.Increased cell-surface urokinase in advanced ovarian cancer.
P2860
Q33781945-A8635011-8EDE-49FE-8CE2-FA5F8CA78F52Q33886514-77852F81-2C78-469C-927B-67F3C13CA8C8Q33907027-62B25A4A-84B1-4500-A82C-3FBDBA1B1CFBQ35240620-4DF0E9E4-EE11-495D-B4C5-FC7DFCC98EA6Q35976072-E6DCD5F3-FC51-466A-9078-405516444600Q35993235-84E787A9-2C61-46DB-AD7C-91F2DF5960C4Q36081353-08CB749E-9DDD-4B87-B88A-90C50F1FE714Q36233440-B1EC80FE-5A9F-4F05-8871-4393C62C957AQ36529534-0B0D7001-E57F-4850-909B-44513ABB4EFFQ37635689-B530B0AD-85BD-4F24-9A56-E6FE06A23089Q40395907-D813A80D-CC7A-4621-BF09-A8126A18C95BQ40642836-B396BA82-8E70-4E67-8AE2-54B77DAD2277Q40642976-FF1A9AAF-2869-45A0-87DD-4A6EECEAC508Q41018821-DA1860B2-CA41-4FB9-AEE0-A5F7DAE6C37EQ41157827-2762A118-6232-40AB-B051-6429716BBB13Q41340665-AA2C950C-B208-42D3-89D0-187D33DE2F82Q41546059-BDC4EB4C-5F18-469A-80D5-1BAA5B2B5E20Q41603494-0CFA8C6D-00C1-48EA-AE60-EEC0CD3B2853Q41832676-643A43E2-F316-4312-B20C-46C38EEDC8EAQ41870321-4D7BCCB4-5630-44C9-ACA7-3A764CCFEB39Q42026966-756E286B-A733-4B14-839A-E3CB73B675E6Q42256420-E5D67ADA-5489-4A17-874D-F6582A04641EQ42372048-E05AF39F-3081-404A-8A07-852092842FB6Q43933765-0637C046-C2A6-4524-9B1D-0EB62226382CQ48017721-6B442619-D44A-419F-ABD0-B150873E2B93Q54521551-54164446-BD72-4057-B40E-B138A01DE576Q55379925-D1E53F17-AFA1-49E1-8A9B-9A32E06EC8C5
P2860
Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.
description
1989 nî lūn-bûn
@nan
1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Mouse L cells expressing human ...... trix degradation and invasion.
@ast
Mouse L cells expressing human ...... trix degradation and invasion.
@en
type
label
Mouse L cells expressing human ...... trix degradation and invasion.
@ast
Mouse L cells expressing human ...... trix degradation and invasion.
@en
prefLabel
Mouse L cells expressing human ...... trix degradation and invasion.
@ast
Mouse L cells expressing human ...... trix degradation and invasion.
@en
P2093
P2860
P356
P1476
Mouse L cells expressing human ...... trix degradation and invasion.
@en
P2093
Liebermann L
Medcalf RL
Schleuning WD
P2860
P304
P356
10.1083/JCB.109.2.915
P407
P577
1989-08-01T00:00:00Z